This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Chemed Corporation Is Being Investigated On Behalf Of Shareholders

Stocks in this article: CHE

SAN DIEGO and CINCINNATI, May 10, 2013 /PRNewswire/ --  Shareholder rights law firm Robbins Arroyo LLP is investigating whether officers and directors of Chemed Corporation (NYSE: CHE) breached their fiduciary duties to shareholders. Chemed, through its subsidiaries, provides hospice services to patients in the United States.


The U.S. Department of Justice Files False Claims Act Lawsuit Against Chemed

On May 2, 2013, U.S. Department of Justice ("DOJ") announced that it filed a lawsuit against Chemed, and several of its wholly owned hospice subsidiaries, alleging that the company falsely billed Medicaid tens of millions of dollars for crisis care hospice services costing taxpayers tens of millions of dollars.  Crisis care is available to patients with acute medical symptoms requiring immediate short-term care, and is billed at the highest daily rate a hospice can bill Medicare. 

Specifically, the lawsuit alleges that the company submitted false claims for crisis services that were not necessary, not performed, or not performed in accordance with Medicare requirements.  Further, the lawsuit also alleges that Chemed knowingly submitted false hospice care claims to Medicare for patients who were not terminally ill.  The DOJ complaint also claims that Chemed pressured its staff to increase crisis care claims regardless of whether the services were appropriate or actually being provided.  On news of the lawsuit, Chemed stock fell $13.79 per share, or nearly 17%, to close at $68.00 per share.

Robbins Arroyo LLP Investigates Failed Internal Controls by Chemed Officers and Directors

Robbins Arroyo LLP's investigation concerns whether certain of Chemed's officers and directors failed to implement adequate internal controls.  In addition, Robbins Arroyo LLP is investigating whether these fiduciaries issued false and misleading statements regarding (i) the company's financial condition, and (ii) the implementation and maintenance of internal controls to ensure that Chemed complied with the federal laws.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs